Polocaine(r) -mpf (mepivacaine Hci)

The dosage of Mepivacaine must be individualized based on the patient's age, weight, physical status, and the specific procedure being performed. Healthcare providers follow the principle of using the lowest effective dose to achieve the desired level of anesthesia.

• Local Infiltration: For minor procedures, doses typically range from 5 mL to 40 mL of a 1% solution (50 mg to 400 mg). The total dose should generally not exceed 400 mg in a single administration.
• Peripheral Nerve Blocks: For major nerve blocks (e.g., brachial plexus), 15 mL to 40 mL of a 1% or 2% solution (150 mg to 800 mg) may be used, though the upper limit is strictly monitored.
• Epidural Anesthesia: Dosages vary significantly based on the level of the spine. Typically, 15 mL to 30 mL of a 1.5% or 2% solution is administered in increments to reach the desired sensory level.
• Dental Procedures: The standard dose for dental infiltration or nerve block is 1.8 mL to 3.6 mL (one to two cartridges) of a 3% solution. The maximum recommended dose for a healthy adult in dentistry is 6.6 mg/kg (3 mg/lb), not to exceed a total of 400 mg.

Mepivacaine is used in pediatric patients, but the dosage must be calculated with extreme caution based on the child's weight and physical condition.

• General Guidelines: The maximum dose for children should generally not exceed 5 mg/kg to 6 mg/kg of body weight. In children under 3 years of age or weighing less than 13 kg (30 lbs), Mepivacaine 3% is often the preferred concentration in dental settings.
• Safety Note: Pediatric patients are at a higher risk for systemic toxicity if the dose is not precisely calculated. Healthcare providers will use the smallest volume necessary to achieve adequate anesthesia.

Renal Impairment

While Mepivacaine is primarily metabolized by the liver, its metabolites are excreted by the kidneys. In patients with severe renal impairment, there is a theoretical risk of metabolite accumulation. However, because the parent drug is rapidly metabolized, dose adjustments are usually not required for single-dose procedures, though caution is advised in repeated dosing.

Hepatic Impairment

Patients with significant liver disease (e.g., cirrhosis, hepatitis) require careful dose reduction. Since the liver is the primary organ responsible for breaking down Mepivacaine, impaired function can lead to toxic plasma levels. Healthcare providers may reduce the total dose by 25% to 50% in patients with severe hepatic dysfunction.

Elderly Patients

Geriatric patients often have reduced physiological reserves and may have undiagnosed cardiovascular or hepatic issues. Lower doses are generally recommended for the elderly to minimize the risk of systemic toxicity and cardiovascular depression. Clinical data suggests that the volume of distribution and clearance may be altered in patients over 65.

Mepivacaine is administered only by healthcare professionals trained in the management of regional anesthesia.

• Administration Route: It is given via subcutaneous infiltration, intramuscular injection near nerves, or epidural injection. It must never be injected directly into a vein (intravenously), as this can cause immediate and severe toxicity.
• Monitoring: During administration, the provider will perform 'aspiration' (pulling back on the syringe) to ensure the needle is not inside a blood vessel.
• Storage: Mepivacaine should be stored at controlled room temperature (20°C to 25°C). Solutions that are discolored or contain particulate matter should not be used.

Since Mepivacaine is administered by a healthcare professional in a clinical or surgical setting for a specific procedure, the concept of a 'missed dose' by a patient does not apply. If a procedure is delayed, the medical team will determine the appropriate timing for the injection.

An overdose of Mepivacaine leads to Local Anesthetic Systemic Toxicity (LAST). This is a medical emergency.

• Signs of Overdose: Initial symptoms include a metallic taste, ringing in the ears (tinnitus), lightheadedness, and numbness around the mouth. This can progress to tremors, seizures, loss of consciousness, and respiratory arrest. Cardiovascular signs include low blood pressure, slow heart rate, and cardiac arrest.
• Emergency Measures: If an overdose is suspected, the administration must be stopped immediately. Treatment involves maintaining the airway, providing 100% oxygen, and administering intravenous lipid emulsion (Intralipid) to 'soak up' the anesthetic from the bloodstream, along with medications to control seizures.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. If you feel any unusual symptoms during or after the injection, notify your medical team immediately.

Most patients tolerate Mepivacaine well, but some local reactions are common due to the nature of the injection and the anesthetic effect.

• Localized Numbness: The primary intended effect is numbness, but this can feel like a heavy, 'dead' sensation in the affected limb or area. This typically resolves within 2 to 4 hours.
• Tingling or 'Pins and Needles': As the medication begins to wear off, patients frequently experience paresthesia (tingling) in the area. This is a normal sign that nerve function is returning.
• Mild Injection Site Pain: Slight soreness or bruising at the site where the needle entered the skin is common and usually fades within 24 to 48 hours.

• Dizziness and Lightheadedness: Some patients may feel slightly faint or dizzy shortly after the injection. This is often a vasovagal response (fainting reflex) to the needle rather than the drug itself.
• Nausea: Mild stomach upset or a feeling of queasiness can occur, particularly if Mepivacaine is used for epidural anesthesia.
• Headache: In the case of epidural or spinal-adjacent blocks, a mild headache may occur. If the headache is severe and worsens when sitting up, it may be a 'post-dural puncture headache,' which requires medical attention.

• Allergic Reactions: True allergies to amide anesthetics like Mepivacaine are extremely rare. Symptoms may include hives (urticaria), itching, or swelling of the face and throat.
• Urinary Retention: When used for epidural anesthesia, Mepivacaine can temporarily affect the nerves that control the bladder, making it difficult to urinate for a few hours.
• Persistent Paresthesia: In very rare cases, numbness or tingling may last for several days or weeks. This is usually due to mechanical nerve irritation from the needle rather than the drug itself.

> Warning: Stop the procedure and alert your doctor immediately if you experience any of the following symptoms of systemic toxicity.

• Central Nervous System (CNS) Toxicity:
• Excitation Phase: Agitation, confusion, talkativeness, or tremors.
• Depression Phase: Slurred speech, extreme drowsiness, seizures, or loss of consciousness.
• Sensory Changes: Visual disturbances (blurred vision), ringing in the ears (tinnitus), or a metallic taste in the mouth.
• Cardiovascular Toxicity:
• Arrhythmias: Irregular heartbeats or a very slow heart rate (bradycardia).
• Hypotension: A sudden drop in blood pressure, leading to fainting or a feeling of impending doom.
• Cardiac Arrest: In extreme cases of accidental intravenous injection, the heart may stop beating.
• Respiratory Distress: Difficulty breathing, shallow breathing, or a complete stop in breathing (respiratory arrest).

Mepivacaine is intended for short-term use during a single procedure. It does not typically cause long-term side effects when administered correctly. However, repeated exposures in a short timeframe can lead to drug accumulation and increased risk of toxicity. There is no evidence that Mepivacaine causes long-term cognitive impairment or organ damage when used in standard clinical doses. Rare reports of long-term nerve damage (neuropathy) are usually associated with the injection technique or the underlying surgical trauma rather than the chemical properties of Mepivacaine itself.

There are currently no FDA black box warnings specifically for Mepivacaine. However, the FDA requires all local anesthetics to carry prominent warnings regarding the risk of Local Anesthetic Systemic Toxicity (LAST) and the potential for severe cardiovascular and neurological events if the drug is accidentally injected into a blood vessel. Additionally, there are warnings regarding the use of local anesthetics in obstetrics, as they can cause fetal bradycardia (slow heart rate).

Report any unusual symptoms to your healthcare provider. Early detection of side effects is key to preventing serious complications.

Mepivacaine should only be administered by clinicians who are well-versed in the diagnosis and management of dose-related toxicity and other acute emergencies that might arise from the block to be employed. Resuscitative equipment, including oxygen, intravenous fluids, and medications for seizure control, must be immediately available. The safety and effectiveness of Mepivacaine depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies.

No FDA black box warnings for Mepivacaine. While it lacks a specific black box warning, it shares the general class warnings for all local anesthetics regarding the risk of systemic toxicity and the need for immediate access to resuscitation equipment.

• Allergic Reactions / Anaphylaxis Risk: While rare with amide anesthetics, hypersensitivity reactions can occur. Patients with a known allergy to other amide-type anesthetics (like lidocaine or bupivacaine) may exhibit cross-sensitivity. Some formulations contain methylparaben as a preservative, which can also trigger allergic reactions.
• Cardiovascular Disease: Mepivacaine should be used with extreme caution in patients with impaired cardiovascular function, especially those with heart block or significant arrhythmias. Local anesthetics can depress myocardial conduction and excitability, potentially worsening pre-existing heart conditions.
• Hepatic Disease: Because Mepivacaine is metabolized by the liver, patients with severe liver disease are at a higher risk of developing toxic plasma concentrations. Dose reductions and careful monitoring are necessary.
• Malignant Hyperthermia: Although the association is weak, there have been rare reports of local anesthetics triggering malignant hyperthermia (a life-threatening reaction to certain anesthetic drugs). Providers should be prepared to treat this with dantrolene if it occurs.
• Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or those taking other oxidizing drugs are at higher risk.

During and after the administration of Mepivacaine, continuous monitoring is essential:

• Vital Signs: Blood pressure, heart rate, and respiratory rate should be checked frequently (every 5-15 minutes) until the anesthetic effect begins to wane.
• Electrocardiogram (ECG): Continuous ECG monitoring is recommended for major nerve blocks or epidural anesthesia to detect early signs of cardiac toxicity.
• Mental Status: The patient should be engaged in conversation to monitor for early CNS signs of toxicity, such as slurred speech or confusion.
• Pulse Oximetry: To ensure adequate oxygenation of the blood.

Patients should be advised that Mepivacaine may temporarily impair motor function and coordination, especially if used for lower extremity blocks or epidural anesthesia. Do not drive or operate heavy machinery until the anesthetic effect has completely worn off and full sensation and muscle strength have returned. This typically takes 4 to 6 hours.

Alcohol should be avoided for at least 24 hours following the administration of Mepivacaine. Alcohol can enhance the central nervous system depressant effects of any residual anesthetic and may interfere with the recovery process. Furthermore, alcohol can increase the risk of falls if the patient still has lingering numbness.

Mepivacaine is a single-use medication for acute procedures; therefore, there is no withdrawal syndrome or tapering requirement. Once the drug is metabolized and cleared from the body, its effects cease entirely.

> Important: Discuss all your medical conditions with your healthcare provider before starting Mepivacaine. Ensure your provider knows if you have a history of heart, liver, or kidney disease.

There are few absolute contraindications for drug combinations with Mepivacaine, but the following should be avoided:

• Other Amide Local Anesthetics: Using Mepivacaine in combination with other amides (e.g., lidocaine, bupivacaine) is generally avoided unless the total dose is carefully calculated to be below toxic thresholds. Their toxic effects are additive.
• Specific Antiarrhythmics: Drugs like tocainide or mexiletine, which are structurally related to local anesthetics, should not be used concurrently as they can significantly increase the risk of systemic toxicity.

• CNS Depressants: Medications such as benzodiazepines (Valium, Xanax), opioids, and barbiturates can increase the risk of respiratory depression and enhance the CNS effects of Mepivacaine. While often used together in surgical settings, they require expert monitoring.
• Class I Antiarrhythmic Drugs: Drugs like quinidine or procainamide can have additive effects on the heart's conduction system when combined with Mepivacaine, potentially leading to severe bradycardia or heart block.
• Beta-Blockers: Medications like propranolol can reduce hepatic blood flow, which may slow the metabolism of Mepivacaine and increase its levels in the blood.

• Cimetidine: This H2-blocker can inhibit the liver enzymes responsible for metabolizing Mepivacaine, potentially leading to higher plasma levels of the anesthetic.
• MAO Inhibitors and Tricyclic Antidepressants: If Mepivacaine were used with epinephrine (though it often isn't), these drugs could cause a dangerous increase in blood pressure. Even without epinephrine, caution is advised due to altered autonomic sensitivity.

• General: There are no known direct interactions between Mepivacaine and specific foods like grapefruit or dairy. However, for most procedures requiring Mepivacaine, patients are instructed to fast (NPO status) for several hours beforehand to prevent complications like aspiration if nausea occurs.
• Caffeine: High intake of caffeine may theoretically increase heart rate and sensitivity, potentially masking or mimicking early signs of anesthetic toxicity.

• St. John’s Wort: This herb induces liver enzymes and could theoretically speed up the metabolism of Mepivacaine, potentially shortening its duration of action.
• Kava and Valerian: These supplements have sedative properties and may enhance the CNS-depressant effects of Mepivacaine.
• Ginkgo Biloba and Garlic: These may increase the risk of bleeding or hematoma at the site of injection, which is a concern for epidural or deep nerve blocks.

• Creatine Phosphokinase (CPK): Intramuscular injection of Mepivacaine may result in an increase in CPK levels, which could be misinterpreted as a sign of a myocardial infarction (heart attack) in a clinical diagnostic setting.
• Methemoglobin levels: Mepivacaine can interfere with the accuracy of pulse oximetry if it induces methemoglobinemia, leading to falsely low oxygen saturation readings.

For each major interaction, the management strategy involves adjusting the dose, choosing an alternative anesthetic, or increasing the frequency of vital sign monitoring.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication reconciliation is vital for your safety during anesthesia.

Mepivacaine must NEVER be used in the following circumstances:

• Known Hypersensitivity: Patients with a documented allergy to Mepivacaine or any other amide-type local anesthetic (e.g., lidocaine, prilocaine, bupivacaine, ropivacaine) must not receive this drug. Anaphylaxis, though rare, can be fatal.
• Hypersensitivity to Parabens: Some multi-dose vials contain methylparaben. Patients with a known allergy to parabens should only receive preservative-free formulations.
• Severe Heart Block: Because Mepivacaine can slow electrical conduction in the heart, it is absolutely contraindicated in patients with second or third-degree heart block without a functioning pacemaker.
• Obstetric Paracervical Block: Mepivacaine is specifically contraindicated for paracervical block anesthesia in obstetrics due to a high risk of fetal bradycardia and death.

Conditions requiring careful risk-benefit analysis include:

• Severe Hepatic Dysfunction: Due to the risk of drug accumulation and systemic toxicity.
• Severe Renal Impairment: Caution is needed due to the accumulation of metabolites.
• Hypovolemia and Shock: In patients with severe blood loss, the cardiovascular depressive effects of Mepivacaine (especially in epidural use) can lead to profound hypotension.
• Myasthenia Gravis: Local anesthetics can theoretically interfere with neuromuscular transmission, potentially worsening muscle weakness in these patients.
• Inflammation or Infection at the Injection Site: Local anesthetics are less effective in acidic, inflamed tissues, and injecting into an infected area can spread the infection.

Patients allergic to 'ester-type' local anesthetics (like procaine, benzocaine, or tetracaine) usually do not show cross-sensitivity to Mepivacaine. However, patients allergic to other 'amides' (the 'i-caine' group where there is an 'i' before the 'caine', such as l-i-docaine) are highly likely to be allergic to Mepivacaine. Always inform your provider of any previous reactions to dental numbing agents or surgical anesthetics.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Mepivacaine. Ensure you disclose all previous surgical and anesthetic experiences.

Mepivacaine is classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans.

• Teratogenicity: There is no clear evidence that Mepivacaine causes birth defects when used for short-term anesthesia.
• Labor and Delivery: Mepivacaine is widely used for epidural anesthesia during labor. However, it readily crosses the placenta. If high doses are used, it can cause fetal bradycardia (slow heart rate), acidosis, and neurological depression in the newborn.
• Obstetric Warning: As noted in contraindications, it should not be used for paracervical blocks due to fetal risk.

It is not known whether Mepivacaine is excreted in human milk. However, because most local anesthetics are excreted in very small amounts and Mepivacaine has a relatively short half-life, it is generally considered safe to resume breastfeeding once the mother has fully recovered from the anesthetic effects. Healthcare providers often suggest waiting 4 to 6 hours after the procedure as a precaution.

Mepivacaine is approved for use in children. However, the risk of systemic toxicity is higher in pediatric populations due to their smaller volume of distribution and potentially immature metabolic pathways.

• Dosing: Must be strictly weight-based (max 5-6 mg/kg).
• Dental Use: It is common in pediatric dentistry, but clinicians must be wary of 'cheek biting' injuries while the child is still numb.

Clinical studies have shown that elderly patients may require lower doses of Mepivacaine.

• Pharmacokinetics: Reduced cardiac output and liver blood flow in the elderly can slow the clearance of the drug.
• Risk Factors: The elderly are more likely to have pre-existing heart disease or be taking multiple medications (polypharmacy) that interact with Mepivacaine.
• Safety: Providers should use the smallest effective dose and monitor cardiovascular status closely.

In patients with end-stage renal disease, the clearance of Mepivacaine metabolites is significantly reduced. While a single dose for a minor procedure is unlikely to cause issues, repeated dosing (such as continuous epidural infusion) should be avoided or monitored with extreme caution. Dialysis does not significantly remove Mepivacaine from the blood due to its high protein binding.

Hepatic impairment is a major concern. Patients with a Child-Pugh score of B or C should receive significantly reduced doses. The half-life of Mepivacaine can double or triple in patients with liver failure, making them highly susceptible to Local Anesthetic Systemic Toxicity (LAST).

> Important: Special populations require individualized medical assessment. Your doctor will adjust the anesthetic plan based on your specific physiological needs.

Mepivacaine is an amide-type local anesthetic that acts by inhibiting the ionic fluxes required for the initiation and conduction of nerve impulses. Its primary target is the voltage-gated sodium channel (Nav1.5 and other subtypes) located in the neuronal cell membrane.

When Mepivacaine is injected near a nerve, the uncharged (base) form of the molecule diffuses across the lipid-rich nerve sheath and membrane. Once inside the axoplasm, the molecule becomes protonated (charged). This charged form binds to the S6 segment of domain IV of the alpha-subunit of the sodium channel. By binding to the internal pore, Mepivacaine prevents the channel from transitioning to its 'open' state, thereby blocking the influx of sodium ions. Without sodium influx, the threshold potential is not reached, and the nerve cannot fire an action potential.

• Onset of Action: Rapid (typically 3 to 5 minutes for infiltration and 10 to 15 minutes for major nerve blocks).
• Duration: Intermediate. Without epinephrine, it lasts 1.5 to 2 hours. With epinephrine, the duration can extend to 3 hours or more.
• Differential Block: Mepivacaine follows a predictable pattern of blockade: Pain > Temperature > Touch > Pressure > Motor function. This allows for 'sensory-motor dissociation' at lower concentrations, where the patient is numb but can still move to some degree.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Systemic after injection) |

| Protein Binding | 75% - 80% (Alpha-1-acid glycoprotein) |

| Half-life | 1.9 - 2.2 hours (Adults); 9 hours (Neonates) |

| Tmax | 30 - 60 minutes (Site dependent) |

| Metabolism | Hepatic (CYP1A2 and others) |

| Excretion | Renal (95% as metabolites, 5% unchanged) |

• Molecular Formula: C15H22N2O (as hydrochloride: C15H22N2O·HCl)
• Molecular Weight: 282.8 g/mol
• Solubility: Freely soluble in water and methanol.
• Structure: Mepivacaine is a pipecoloxylidide derivative, structurally related to bupivacaine but with a methyl group instead of a butyl group on the piperidine ring.

Mepivacaine is classified as a Local Anesthetic, Amide-type. It is in the same therapeutic class as lidocaine, bupivacaine, ropivacaine, and prilocaine. It is distinguished from ester-type anesthetics (like cocaine and procaine) by its amide linkage, which makes it more stable and less likely to cause allergic reactions.